Daiichi Sankyo on Path to Net 2 Trillion Yen in Sales by FY2025 on Robust Core Products

Daiichi Sankyo President and COO Hiroyuki Okuzawa (Courtesy of Daiichi Sankyo) Daiichi Sankyo saw its sales expand 22.4% over the year in FY2022 propelled by the growth of its cancer drug Enhertu (trastuzumab deruxtecan) and other mainstay products. Fueled by...read more